SolasCure

SolasCure is a UK-based startup dedicated to revolutionizing chronic wound care with its breakthrough enzymatic technology. The company's flagship product, Aurase Wound Gel, is designed to address the unmet needs in chronic wound care, catering to both hospitals, clinics, and homes. This product, comprised of tarumase, a highly-specific fibrinolytic enzyme isolated & cloned from maggot saliva in a hydrogel, aims to provide an easy-to-use, effective solution for wound debridement and preparation. Aurase Wound Gel has successfully completed Phase IIa trials, demonstrating its safety, effectiveness, and pain-free application. The company has received notable recognition and grants, such as the Biomedical Catalyst Grant from Innovate UK, the EIC Accelerator Grant from the European Innovation Council, and the Life Sciences Innovator award from the UK Department for Trade and Business. Furthermore, SolasCure is the winner of the 2019 URGO Mentorship Programme. Founded in 2017 as a spin-off from BRAIN Biotech AG, SolasCure has shown significant promise in the biopharma, biotechnology, and healthcare industries. With its headquarters in Cambridge, UK, the company is poised to make a significant impact in the field of chronic wound care. For more information, visit their website at www.solascure.com.